PDCD1 and neoplasm: Indeed, the approval of blocking antibodies against CTLA-4, PD1 or its ligand PDL1 was a major breakthrough in immune therapy and had a strong impact on the treatment of patients suffering on metastatic melanoma, lung cancer and several other tumor entities 1-3.